The potential for improving cardio-renal outcomes in chronic kidney disease with the aldosterone synthase inhibitor vicadrostat (BI 690517): a rationale for the EASi-KIDNEY trial.
Judge PK. et al, (2024), Nephrol Dial Transplant
In adults with BMI ≥27 kg/m2 and CVD, but without diabetes, semaglutide reduced MACE, regardless of baseline HbA1c level.
Zhu D. and Herrington WG., (2024), Ann Intern Med
In HF, T2D, CKD, or atherosclerotic CVD, SGLT2 inhibitors reduce HF hospitalizations and CV mortality.
Zhu D. and Herrington WG., (2024), Ann Intern Med
Alcohol and mortality in Mexico: prospective study of 150 000 adults.
Trichia E. et al, (2024), Lancet Public Health, 9, e907 - e915
Design considerations for future renoprotection trials in the era of multiple therapies for chronic kidney disease
ZHU D. et al, (2024), NDT International
Empagliflozin lowers serum uric acid in chronic kidney disease: exploratory analyses from the EMPA-KIDNEY trial
Mayne K. et al, (2024), Nephrology Dialysis Transplantation
Diabetic Kidney Disease - Semaglutide Flows into the Mainstream.
Herrington WG. and Haynes R., (2024), N Engl J Med, 391, 178 - 179
Heart failure events in randomized controlled trials for adults receiving maintenance dialysis: a meta-epidemiologic study.
Collister D. et al, (2024), Nephrol Dial Transplant
Frailty, multimorbidity and polypharmacy: exploratory analyses of the effects of empagliflozin from the EMPA-KIDNEY trial
Mayne K. and HERRINGTON W., (2024), American Society of Nephrology. Clinical Journal
Effects of statin therapy on diagnoses of new-onset diabetes and worsening glycaemia in large-scale randomised blinded statin trials: an individual participant data meta-analysis.
Cholesterol Treatment Trialists’ (CTT) Collaboration. Electronic address: ctt@ndph.ox.ac.uk None. and Cholesterol Treatment Trialists’ (CTT) Collaboration None., (2024), Lancet Diabetes Endocrinol, 12, 306 - 319
Effects of SGLT2 inhibitors on cause-specific cardiovascular death in patients with chronic kidney disease: a meta-analysis of CKD progression trials.
Fletcher RA. et al, (2024), Clin J Am Soc Nephrol
Sodium Glucose Co-transporter 2 Inhibitors and Major Adverse Cardiovascular Outcomes: A SMART-C Collaborative Meta-Analysis.
Patel SM. et al, (2024), Circulation
Executive summary of the KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease: known knowns and known unknowns
Levin A. et al, (2024), Kidney International, 105, 684 - 701
KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease.
Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group None., (2024), Kidney Int, 105, S117 - S314
EFFECTS OF EMPAGLIFLOZIN IN PATIENTS WITH CHRONIC KIDNEY DISEASE FROM JAPAN: EXPLORATORY ANALYSES FROM EMPA-KIDNEY
HERRINGTON W., (2024), Clinical and Experimental Nephrology
[2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes].
Marx N. et al, (2024), G Ital Cardiol (Rome), 25, e1 - e103
Efficacy and safety of SGLT2 inhibitors with and without glucagon-like peptide 1 receptor agonists: a SMART-C collaborative meta-analysis of randomised controlled trials
Apperloo EM. et al, (2024), The Lancet Diabetes and Endocrinology
Effects of Empagliflozin on Fluid Overload, Weight and Blood Pressure in Chronic Kidney Disease
Mayne K. et al, (2023), Journal of the American Society of Nephrology
SGLT2i for evidence-based cardiorenal protection in diabetic and non-diabetic chronic kidney disease: a comprehensive review by EURECA-m and ERBP working groups of ERA
Mark PB. et al, (2023), Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 38, 2444 - 2455
Effects of empagliflozin on progression of chronic kidney disease: a pre-specified secondary analysis from the EMPA-KIDNEY trial
HAYNES R. et al, (2023), Lancet Diabetes and Endocrinology